• 1
    Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis 2012; 59: 874885.
  • 2
    Arroyo V, Fernández J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 8195.
  • 3
    Fagundes C, Pepin MN, Guevara, Barreto R, Casals G, Solà E, et al. Urinary neutrophil gelatinase-lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 2012; 57: 267273.
  • 4
    Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 23622370.
  • 5
    Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 13101318.
  • 6
    Ginès P, Angeli P, Lenz K, Moller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397417.
  • 7
    Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al.; for Terlipressin Study Group. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Gastroenterology 2008; 134: 13601368.
  • 8
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al.; for TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 13521359.
  • 9
    Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576584.
  • 10
    Angeli P, Fasolato S, Cavallin M, et al. Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type-1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical trial. Hepatology 2008; 48: 378A.
  • 11
    Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009: 137: 11791181.
  • 12
    Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56: 12931298.
  • 13
    Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 5564.
  • 14
    Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742748.
  • 15
    Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43: 680685.
  • 16
    Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation 2011; 91: 11411147.
  • 17
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416422.
  • 18
    Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000: 47: 288295.
  • 19
    Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al.; for HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782789.e3.
  • 20
    Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, et al.; for International Liver Transplantation Society Expert Panel. Report of the first international Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: S1S34.
  • 21
    Angeli P, Ginès P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol 2012; 57: 11351140.